-
05-21
2026
CTC, ctDNA, or Tumor Markers: Which One Should You Choose for Cancer Testing?
In the era of precision oncology, liquid biopsy technologies are reshaping the landscape of cancer diagnosis and treatment. Among them, circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and traditional tumor markers are hailed as the "three musketeers of liquid biopsy." What exactly are they? What information can each provide for patients? This article will clarify everything in one go.
View
-
04-03
2026
New possibilities for liquid biopsy: Two breakthroughs of circulating tumor cells in precision cancer medicine
Combining the groundbreaking studies by Labyrinth Biotech published in Frontiers in Oncology and Cancer Treatment and Research Communications, understand the breakthrough progress of CTCs in early screening and drug selection
View
-
01-12
2026
Conference: Labyrinth Participates in the 1st Anniversary International Symposium of the School of Biomedical Sciences at City University of Hong Kong
Majid E. Warkiani, Chief Technology Officer of Labyrinth and Professor at the University of Technology Sydney, was invited as a speaker and delivered a keynote report: 'Microfluidic and AI-Driven Platforms for Next-Generation Assisted Reproduction'
View
-
12-19
2025
The Second Half of Liquid Biopsy: How Platform Companies Access Clinical Practice
Liquid biopsy companies no longer just deliver test reports to hospitals or patients; they are beginning to push the test results into subsequent treatment stages, affecting the entire process from early screening to treatment.
View
-
12-01
2025
Conference: The Tumor Smart-Link International Symposium was successfully held in Suzhou, bringing together domestic and international experts to discuss innovative technologies and translation.
On November 29, 2025, the international seminar 'Intelligent Oncology: Empowering Precision Medical Transformation with Artificial Intelligence and Innovative Technology' hosted by Suzhou Labrys Biotech Co., Ltd. was successfully held and concluded in Suzhou.
View
-
11-27
2025
Real Case: When Imaging Falls Behind, CTC Speaks First: Precise Detection Helps Her Smoothly Access Insurance-Covered Treatment
CTC detection technology is like a precise 'scout,' providing patients and doctors with critical information about the disease and treatment options at every important stage of cancer, from early screening to ADC drug screening.
View
-
07-01
2025
Things About Drug Sensitivity
Let me introduce a technology that can bring a major breakthrough in cancer treatment—the CTC drug sensitivity test.
View
-
05-28
2025
International Exchange: Labyrinth Equipment Installed at the National University of Singapore Public Platform to Support Globalized Precision Medical Research
The cell sorter CE01 independently developed by Suzhou Labyrinth Biotechnology Co., Ltd. has officially been installed in the Flow Cytometry Unit of the Yong Loo Lin School of Medicine at the National University of Singapore (NUS).
View